血液内科研究業績

2024年

1.学会発表等

1-1 高桑輝人,岡山裕介,山中英治: 「血液連携パス」を活用した拠点病院と地域医療との橋渡し, 第24回日本クリニカルパス学会学術集会, 愛媛, 2024.10.04-05(一般口演)
1-2 高桑輝人:berdomide, daratumumab, and dexamethasone (IberDd)in newly diagnosed multiple myeloma (NDMM), 第86回日本血液学会学術集会, 京都, 2024.10.11-13(一般口演)
1-3 高桑輝人: IsaKd versus IsaPd: A multicenter propensity score matched retrospective analysis, 第86回日本血液学会学術集会, 京都, 2024.10.11-13(一般口演)
1-4 高桑輝人:Fulminant delayed toxicity in the gastrointestinal tract after CAR-T cell therapy, 第86回日本血液学会学術集会, 京都, 2024.10.11-13(一般口演)
1-5 高桑輝人:Predicting efficacy of isatuximab + pomalidomide for multiple myeloma by lymphocyte/monocyte ratio, 第86回日本血液学会学術集会, 京都, 2024.10.11-13(一般口演)
1-6 高桑輝人,岡山裕介:Drug interactions between posaconazole and tacrolimus by route of administration, 第86回日本血液学会学術集会, 京都, 2024.10.11-13(一般口演)
1-7 岡山裕介,高桑輝人:High day 7 posaconazole concentration is a risk factor for hypokalemia, 第86回日本血液学会学術集会, 京都, 2024.10.11-13(一般口演)
1-8 高桑輝人:Japan phase 1/2 study of fedratinib in JAK inhibitorpretreated/-untreated myelofibrosis (MF-003), 第86回日本血液学会学術集会, 京都, 2024.10.11-13(一般口演)
1-9 高桑輝人:Severe diarrhea as an immune-related adverse event of epcoritamab in two cases of refractory DLBCL, 第86回日本血液学会学術集会, 京都, 2024.10.11-13(一般口演)
1-10 高桑輝人:Phase I Safety Study of Anti-Transferrin Receptor 1 Antibody (PPMX-T003) in Patients with Polycythemia Vera and Erythrocythemia,66th ASH Annual Meeting, San Diego,2024.12.07-10(ポスター発表)
1-10 岡山裕介:血液疾患患者におけるポサコナゾールの血中濃度に影響する遺伝子多型を含む因子解析,第34回日本医療薬学会年会, 千葉,2024.11.03(一般口演)

2.学術論文

2-1 高桑輝人:Invasive fungal infection caused by Blastobotrys mokoenaii in an immunocompromised patient with acute myeloid leukemia: A case report, J Infect Chemother 30(6), : 557-561,2024,(症例報告)
2-2 高桑輝人: Comparison of long-term outcomes after first HLA-mismatched unrelated donor transplantation with single unrelated cord blood transplantation using reduced-intensity or reduced-toxicity conditioning, Transpl lmmunol 82, : 101988,2024,(原著)
2-3 岡山裕介,高桑輝人: Pretransplant hepatomegaly is linked to relapse in patients with leukemia and myelodysplastic syndrome not in remission, Int J Hematol 119(3), : 316-326,2024,(原著)
2-4 高桑輝人: A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma, Bone Marrow Transplant 59(5), : 695-698,2024,(Letter)
2-5 高桑輝人: Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem cell transplantation is a risk factor for death in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia, Ann Hematol 103(6), : 2059-2072,2024,(原著)
2-6 高桑輝人: Lymphoproliferative disorder progressing after partial remission following immunosuppressive drugs withdrawal in a patient with rheumatoid arthritis, Mod Rheumatol Case Rep 8(2), : 243-248,2024,(症例報告)
2-7 高桑輝人: Impacts of Posttransplant Cyclophosphamide Dose on Graft-versus-leukemia Effects via HLA-B Leader in HLA-haploidentical Peripheral Blood Stem Cell Transplantation, Acta Haematol 147(6), : 661-670,2024,(原著)
2-8 高桑輝人: Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study, Ann Hematol 103(12), : 5681-5690,2024,(原著)
2-9 高桑輝人: Autotaxin is a potential predictive marker for the development of veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation, Ann Hematol 103(5), : 1705-1715,2024,(原著)
2-10 高桑輝人: Usefulness of web-based application for health surveys before and after peripheral blood stem cell harvest from healthy donors, Rinsho Ketsueki 65(5), : 321-329,2024,(原著)
2-11 高桑輝人: Successful treatment with mesenchymal stem cells for steroid-refractory late-onset idiopathic pneumonia syndrome following allogeneic hematopoietic cell transplantation, Transpl lmmunol 86, : 102-107,2024,(症例報告)
2-12 高桑輝人: T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity “graft-versus-leukemia effects”, Blood Cancer J 14(1), : 79,2024,(原著)
2-13 高桑輝人: The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients, Cancer Immunol Immunother 73(7), : 135,2024,(原著)
2-14 高桑輝人: Dynamic Relapse Prediction by Peripheral Blood WT1mRNA after Allogeneic Hematopoietic Cell Transplantation for Myeloid Neoplasms, Transplant Cell Ther 30(11), : 1088.e1-1088.e12,2024,(原著)
2-15 高桑輝人: The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients, Ann Hematol 103(12), : 5639-5649,2024,(原著)
2-16 高桑輝人: Posttransplantation cyclophosphamide mediates effective reconstitution of memory B cells after allogeneic hematopoietic cell transplantation, Eur J Haematol 113(5), : 651-663,2024,(原著)
2-17 岡山裕介: A case of posttransplant isolated extramedullary relapse of acute lymphoblastic leukemia achieving durable treatment-free remission with blinatumomab and donor lymphocyte infusion, Int J Hematol 120, : 645-650,2024,(原著)